GMP-Certified API Manufacturing in India: A Global Supply Hub
India accounts for approximately 20% of global generic drug production by volume and is home to over 1,500 WHO-GMP certified API manufacturing facilities. The Central Drugs Standard Control Organisation (CDSCO) maintains the official registry of WHO-GMP certified units, with the highest concentration in Gujarat (684 certified units), Maharashtra (229), and Himachal Pradesh (202).
Regulatory Landscape
Indian API manufacturers operate under a multi-layered regulatory framework. Domestic compliance is governed by the Drugs and Cosmetics Act, 1940, enforced by the CDSCO. For export markets, manufacturers pursue certifications from international bodies:
- WHO-GMP
- Baseline requirement for export to emerging markets; over 1,400 Indian facilities currently certified
- USFDA
- Required for the US market; India has the highest number of USFDA-approved plants outside the US
- EU-GMP / EDQM
- Certificate of Suitability (CEP) required for European market access
- PMDA (Japan)
- Growing approval base as Japanese generics market expands
Key Manufacturing Clusters
| Region | Specialization | Notable Companies |
|---|---|---|
| Hyderabad, Telangana | Bulk APIs, anti-retrovirals, custom synthesis | Dr. Reddy's, Aurobindo, Laurus Labs, MSN Laboratories |
| Mumbai & Raigad, Maharashtra | Respiratory APIs, oncology intermediates | Cipla, Sun Pharma, Glenmark |
| Gujarat (Ahmedabad, Vadodara) | Formulation-linked APIs, cardiovascular | Torrent Pharma, Cadila Healthcare |
| Visakhapatnam, AP | Fermentation-based APIs, large-scale synthesis | Divis Laboratories, Laurus Labs |
Market Dynamics
India's API sector has benefited from global supply chain diversification efforts, particularly since 2020, with the Indian government's Production Linked Incentive (PLI) scheme allocating over INR 6,940 crore to boost domestic API production for 53 critical drug intermediates and APIs. This includes key starting materials (KSMs) where India previously depended heavily on Chinese imports.
What Buyers Should Evaluate
When sourcing APIs from Indian manufacturers, procurement teams should verify:
- Current GMP status — check CDSCO's WHO-GMP list and the FDA's inspection database for recent audit outcomes
- Drug Master File (DMF) filings — active DMFs with the USFDA or CEPs with EDQM indicate export readiness
- Capacity and supply reliability — multi-site manufacturers offer redundancy; single-site suppliers carry higher risk
- Vertical integration — manufacturers producing from KSMs through to finished APIs reduce supply chain vulnerability